12:00 AM
 | 
Dec 04, 2000
 |  BC Week In Review  |  Clinical News  |  Regulatory

6-hydroxy-buspirone regulatory update

BMY received U.S. Patent No. 6,150,365 covering the use of 6-hydroxy-buspirone, a metabolite of BMY's marketed BuSpar buspirone anxiolytic...

Read the full 83 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >